The Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences, has reopened Using Point-of-Care Diagnostic Strategies to Advance Elimination of Hepatitis C Infection. The official COMMBUYS solicitation is BD-27-1031-ADMIN-ADM07-132007, reference 264827, and remains open. The Commonwealth states that the procurement was reopened to allow additional applicants and broaden geographic and setting representation.
Funding and deadline
BIDLS intends to award approximately $70,660 total to support two awards of approximately $35,000 per selected agency. Electronic responses are due September 15, 2026 at 5:00 PM Eastern Time. Massachusetts COMMBUYS guidance states that Bid Opening Date/Time values displayed in COMMBUYS are Eastern Time and that the COMMBUYS system clock is the official time of record.
Purpose and eligible setting
The solicitation supports enhancement and expansion of hepatitis C virus testing and linkage to curative treatment in high-impact health care and social-service settings serving people who use injection drugs. Applicants must satisfy the complete reopened RFR requirements. The official COMMBUYS record lists the reopened RFR, evaluation criteria, program budget, and procurement-procedure materials as solicitation attachments.
Point-of-care system
The Commonwealth states that the effort will use a testing system that enables diagnosis of current HCV infection at the point of care and identifies the Cepheid GeneXpert system as the currently approved system for this purpose in the United States.
Submission and procurement controls
COMMBUYS permits electronic quotes. The bid is a non-statewide, Open Market solicitation using a Blanket purchase method and is not SBPP eligible. The current COMMBUYS header lists a contract begin date of November 1, 2026 and end date of December 31, 2027. Applicants should review the complete reopened RFR, evaluation criteria, program budget, required quote attachments, procurement documents, and any later addenda or amendments before submission.
Atlas assessment
Atlas Opportunity Score: 84/100. This is a legitimate Massachusetts healthcare/public-health opportunity with a defined diagnostic objective and a short remaining response window.
N9+ Fit: 0/100. QC Healthcare Fit: 0/100. Dr. Miltie direct-applicant fit: 0/100. The solicitation specifically centers HCV point-of-care diagnosis using the approved Cepheid GeneXpert system. Atlas is not treating the Nonagon N9+ remote physical examination platform as the required HCV diagnostic system and is not forcing a fit.
Contacts
The COMMBUYS information contacts are Ciara Williams at Ciara.Williams@mass.gov and Liisa Randall at liisa.randall@mass.gov. The DPH procurement team is listed at dphprocurementteam@state.ma.us, 617-624-5800.
Official source: COMMBUYS BD-27-1031-ADMIN-ADM07-132007.